Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart + Anlotinib vs Tislelizumab in First-line Extensive-stage Small Cell Lung Cancer
NCT06897579Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart, anlotinib in small cell lung cancer (SCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: terminated.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06897579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897579.